Future Fields, a pioneering biotechnology company that has built the world’s first synthetic biology system to use fruit flies for recombinant protein production, and Jenthera Therapeutics, a gene editing company focused on delivery of the CRISPR ribonucleoproteins (RNPs), today announced a collaboration focused on the manufacturing of a first-of-its-kind cancer-fighting protein. The Future Fields platform, the EntoEngine™, will be used to mass-produce this novel protein under development more sustainably and cost-effectively than conventional approaches to biopharmaceutical production techniques. Future Fields is actively engaging with big and small biotech companies alike to form research collaborations for strategic proteins of interest. The company is well-positioned with its flexible platform to take the lead in sustainably mass-producing specific, complex proteins cost-effectively and at scale.

Harnessing the power of CRISPR, Jenthera Therapeutics has created a new, safer in vivo delivery mechanism for protein-based drugs via intravenous injection, eliminating the use of viruses, lipids or nanoparticles, which are expensive to produce and require large manufacturing facilities. Following sustainable production with the EntoEngine™, Jenthera can deliver tailored gene editing complexes that selectively target the genomes of cancer cells, delivering in vivo anti-cancer therapeutics. The direct delivery of the ribonucleoprotein presents the optimal safety profile in terms of off-target incidence and immunogenicity. In clinically relevant models in vivo, Jenthera’s gene editing complexes have shown high efficacy and tolerance, excellent bio distribution and safety from off-targets and immunogenicity.

“This collaboration with Future Fields reflects our commitment to seeking new and innovative approaches to cost-effectively provide high-quality gene editing biologics at scale, and enable us to advance our sustainability goals,” said Philip Roche, PhD, CEO of Jenthera Therapeutics. “With the EntoEngine™ platform, we can achieve large yields of our novel protein therapeutic, and spool up towards GMP much faster than other cell-based methods. This is integral to our strategy of delivering groundbreaking therapeutics and transforming oncology.”

Future Fields is advancing a new biomanufacturing paradigm by harnessing fruit flies. With its biomanufacturing platform, the EntoEngine™, the company is focused on making significant strides to increase the supply of recombinant proteins for biological drugs, shrink the cost of research and development, and diminish the carbon footprint of bioreactors. Future Fields aims to help the biopharmaceutical industry reduce the carbon impact caused by traditional bioreactors and enhance sustainability through synthetic biology.

“We’re incredibly excited to partner with the Jenthera team to bring cutting-edge, low-cost, and sustainable therapeutic proteins to patients in the clinical setting,” said Matt Anderson-Baron, co-founder and CEO of Future Fields. “This partnership is the first of many demonstrations of the EntoEngine’s capabilities for revolutionizing biologics production and we’re excited to be starting with Jenthera’s groundbreaking technology in high-fidelity gene-editing complexes. The potential impact of this partnership on treating human diseases is limitless.”